Gabather AB engages in the research and development of drug candidates for treatment of diseases affecting the central nervous system. It focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics and cognition-enhancing treatments. The company was founded by Bert Roland Kari Junno, Olov Arvid Sterner, and Mogens Nielsen on November 3, 2014 and is headquartered in Sodertalje, Sweden.